CA2964625C - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Download PDF

Info

Publication number
CA2964625C
CA2964625C CA2964625A CA2964625A CA2964625C CA 2964625 C CA2964625 C CA 2964625C CA 2964625 A CA2964625 A CA 2964625A CA 2964625 A CA2964625 A CA 2964625A CA 2964625 C CA2964625 C CA 2964625C
Authority
CA
Canada
Prior art keywords
compound
liver disease
fatty liver
receptor
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2964625A
Other languages
English (en)
French (fr)
Other versions
CA2964625A1 (en
Inventor
Joseph K. Belanoff
Hazel Hunt
Onno C. MEIJER
Jose VAN DEN HEUVEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CA2964625A1 publication Critical patent/CA2964625A1/en
Application granted granted Critical
Publication of CA2964625C publication Critical patent/CA2964625C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2964625A 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Active CA2964625C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
CA2964625A1 CA2964625A1 (en) 2016-04-21
CA2964625C true CA2964625C (en) 2023-03-07

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964625A Active CA2964625C (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435956B1 (ko) 2014-10-15 2022-08-23 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법
CA3102099C (en) * 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
EP3941460B1 (en) 2019-03-18 2025-10-15 Nieman, Lynnette K. Mifepristone for use in improving insulin sensitivity
WO2021226260A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
IL297840A (en) * 2020-05-06 2023-01-01 Corcept Therapeutics Inc Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
CN116848092A (zh) * 2020-12-21 2023-10-03 科赛普特治疗公司 制备嘧啶环己基糖皮质激素受体调节剂的方法
EP4333848A4 (en) * 2021-05-05 2025-03-19 Corcept Therapeutics Incorporated Methods for reducing liver fat and treating fatty liver disease
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7745657B2 (en) 2005-05-18 2010-06-29 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2158203A2 (en) * 2007-04-13 2010-03-03 Schering Corporation Pyrimidinedione derivatives and use thereof
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
PH12013501906A1 (en) * 2011-03-18 2013-12-16 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102435956B1 (ko) 2014-10-15 2022-08-23 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 및 미네랄로코르티코이드 수용체 길항제를 사용한 지방간 질환 치료법

Also Published As

Publication number Publication date
RU2017114596A3 (enExample) 2019-05-08
US20190151318A1 (en) 2019-05-23
EP3206692A1 (en) 2017-08-23
IL251729B (en) 2020-03-31
JP2017531013A (ja) 2017-10-19
PT3206692T (pt) 2024-04-30
AU2015333645A1 (en) 2017-05-04
RU2017114596A (ru) 2018-11-15
EP3206692B1 (en) 2024-04-03
PH12017500710B1 (en) 2024-01-17
MX2017004943A (es) 2017-07-19
CN107106562A (zh) 2017-08-29
WO2016061195A1 (en) 2016-04-21
CN111557942B (zh) 2023-10-03
EP4353310A3 (en) 2024-06-19
EP3206692A4 (en) 2018-05-30
US10238659B2 (en) 2019-03-26
SG11201703024VA (en) 2017-05-30
NZ731060A (en) 2023-07-28
ES2978871T3 (es) 2024-09-23
CN107106562B (zh) 2020-08-18
FI3206692T3 (fi) 2024-05-06
EP4353310A2 (en) 2024-04-17
RU2718921C2 (ru) 2020-04-15
BR112017007860B1 (pt) 2023-03-07
BR112017007860A2 (pt) 2018-01-16
US20160106749A1 (en) 2016-04-21
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
DK3206692T3 (da) 2024-04-29
CA2964625A1 (en) 2016-04-21
PL3206692T3 (pl) 2024-07-22
KR102435956B1 (ko) 2022-08-23
AU2015333645B2 (en) 2020-01-30
UA123537C2 (uk) 2021-04-21
IL251729A0 (en) 2017-06-29
JP6761410B2 (ja) 2020-09-23
PH12017500710A1 (en) 2017-10-09
US20210085682A1 (en) 2021-03-25
KR20170066646A (ko) 2017-06-14
US11590135B2 (en) 2023-02-28
ZA201702813B (en) 2019-05-29
US12226417B2 (en) 2025-02-18
US20230218621A1 (en) 2023-07-13
CN111557942A (zh) 2020-08-21

Similar Documents

Publication Publication Date Title
US12226417B2 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
Mejia et al. Evaluation and differential diagnosis of marked, persistent eosinophilia
Dragovic et al. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man
US9321736B2 (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
EP1838320A2 (en) Cxcr4 antagonists for the treatment of medical disorders
US11793810B2 (en) Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
WO2008008854A9 (en) Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
KR20180116372A (ko) 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도
CA3182272A1 (en) Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (zh) 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
EP2055697A1 (en) Design and synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs
BR112018067330B1 (pt) Uso de moduladores de receptor de glicocorticoide para potencializar inibidores de sinalização
HK1192411B (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905